Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 113,600 | 89,130 | 92,710 | 80,871 | 78,964 |
| Marketable Securities | 623,438 | 765,295 | 860,150 | 858,066 | 814,411 |
| Receivables | 16,132 | 10,577 | 5,029 | 4,986 | 3,344 |
| Inventories | 35,087 | 32,920 | 32,034 | 30,848 | 29,605 |
| TOTAL | $834,843 | $942,052 | $1,033,109 | $1,019,464 | $968,616 |
| Non-Current Assets | |||||
| PPE Net | 10,566 | 10,775 | 10,675 | 10,579 | 11,067 |
| Investments And Advances | 308,454 | 310,013 | 304,341 | 400,467 | 531,253 |
| Other Non-Current Assets | 31,127 | 34,385 | 37,580 | 40,727 | 44,582 |
| TOTAL | $350,147 | $355,173 | $352,596 | $451,773 | $586,902 |
| Total Assets | $1,184,990 | $1,297,225 | $1,385,705 | $1,471,237 | $1,555,518 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 13,747 | 18,355 | 19,553 | 17,532 | 13,726 |
| Accrued Expenses | 26,293 | 45,459 | 37,217 | 35,289 | 20,761 |
| TOTAL | $58,845 | $82,206 | $74,757 | $70,410 | $52,366 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 17,030 | 21,905 | 26,618 | 31,272 | 36,624 |
| TOTAL | $17,030 | $21,905 | $26,618 | $31,272 | $36,624 |
| Total Liabilities | $75,875 | $104,111 | $101,375 | $101,682 | $88,990 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 59,472 | 58,592 | 58,314 | 58,102 | 57,915 |
| Common Shares | 76 | 75 | 74 | 74 | 74 |
| Retained earnings | -660,816 | -561,705 | -453,666 | -350,233 | -238,213 |
| Other shareholders' equity | -800 | 1,707 | 1,565 | 169 | -121 |
| TOTAL | $1,109,115 | $1,193,114 | $1,284,330 | $1,369,555 | $1,466,528 |
| Total Liabilities And Equity | $1,184,990 | $1,297,225 | $1,385,705 | $1,471,237 | $1,555,518 |